165 related articles for article (PubMed ID: 30051771)
21. Structural and ligand-binding analysis of the YAP-binding domain of transcription factor TEAD4.
Li Y; Liu S; Ng EY; Li R; Poulsen A; Hill J; Pobbati AV; Hung AW; Hong W; Keller TH; Kang C
Biochem J; 2018 Jun; 475(12):2043-2055. PubMed ID: 29760238
[TBL] [Abstract][Full Text] [Related]
22. Computational study of the binding mechanism between farnesoid X receptor α and antagonist N-benzyl-N-(3-(tertbutyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) benzamide.
Du J; Qiu M; Guo L; Yao X
J Biomol Struct Dyn; 2019 Apr; 37(6):1628-1640. PubMed ID: 29633919
[TBL] [Abstract][Full Text] [Related]
23. The Tumor Suppressor Interferon Regulatory Factor 2 Binding Protein 2 Regulates Hippo Pathway in Liver Cancer by a Feedback Loop in Mice.
Feng X; Lu T; Li J; Yang R; Hu L; Ye Y; Mao F; He L; Xu J; Wang Z; Liu Y; Zhang Y; Ji H; Zhao Y; Cheng S; Tian W; Zhang L
Hepatology; 2020 Jun; 71(6):1988-2004. PubMed ID: 31538665
[TBL] [Abstract][Full Text] [Related]
24. High YAP and TEAD4 immunolabelings are associated with poor prognosis in patients with gallbladder cancer.
Kim JY; Sung YN; Hong SM
APMIS; 2021 Dec; 129(12):729-742. PubMed ID: 34779030
[TBL] [Abstract][Full Text] [Related]
25. VGLL4-TEAD1 promotes vascular smooth muscle cell differentiation from human pluripotent stem cells via TET2.
Wang Z; Quan Y; Hu M; Xu Y; Chen Y; Jin P; Ma J; Chen X; Fan J; Fan X; Gong Y; Li M; Wang Y
J Mol Cell Cardiol; 2023 Mar; 176():21-32. PubMed ID: 36657637
[TBL] [Abstract][Full Text] [Related]
26. N-terminal β-strand in YAP is critical for stronger binding to scalloped relative to TEAD transcription factor.
Bokhovchuk F; Mesrouze Y; Meyerhofer M; Fontana P; Zimmermann C; Villard F; Erdmann D; Kallen J; Scheufler C; Velez-Vega C; Chène P
Protein Sci; 2023 Jan; 32(1):e4545. PubMed ID: 36522189
[TBL] [Abstract][Full Text] [Related]
27. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex.
Zhang W; Gao Y; Li P; Shi Z; Guo T; Li F; Han X; Feng Y; Zheng C; Wang Z; Li F; Chen H; Zhou Z; Zhang L; Ji H
Cell Res; 2014 Mar; 24(3):331-43. PubMed ID: 24458094
[TBL] [Abstract][Full Text] [Related]
28. Leveraging the Fragment Molecular Orbital and MM-GBSA Methods in Virtual Screening for the Discovery of Novel Non-Covalent Inhibitors Targeting the TEAD Lipid Binding Pocket.
Kim J; Jin H; Kim J; Cho SY; Moon S; Wang J; Mao J; No KT
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791396
[TBL] [Abstract][Full Text] [Related]
29. Structural and Functional Overview of TEAD4 in Cancer Biology.
Chen M; Huang B; Zhu L; Chen K; Liu M; Zhong C
Onco Targets Ther; 2020; 13():9865-9874. PubMed ID: 33116572
[TBL] [Abstract][Full Text] [Related]
30. Ubiquitin-specific protease 11 (USP11) functions as a tumor suppressor through deubiquitinating and stabilizing VGLL4 protein.
Zhang E; Shen B; Mu X; Qin Y; Zhang F; Liu Y; Xiao J; Zhang P; Wang C; Tan M; Fan Y
Am J Cancer Res; 2016; 6(12):2901-2909. PubMed ID: 28042509
[TBL] [Abstract][Full Text] [Related]
31. VGLL4 inhibits EMT in part through suppressing Wnt/β-catenin signaling pathway in gastric cancer.
Li H; Wang Z; Zhang W; Qian K; Liao G; Xu W; Zhang S
Med Oncol; 2015 Mar; 32(3):83. PubMed ID: 25701461
[TBL] [Abstract][Full Text] [Related]
32. Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEAD⋅Yap Protein-Protein Interaction.
Bum-Erdene K; Zhou D; Gonzalez-Gutierrez G; Ghozayel MK; Si Y; Xu D; Shannon HE; Bailey BJ; Corson TW; Pollok KE; Wells CD; Meroueh SO
Cell Chem Biol; 2019 Mar; 26(3):378-389.e13. PubMed ID: 30581134
[TBL] [Abstract][Full Text] [Related]
33. Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy.
Pobbati AV; Han X; Hung AW; Weiguang S; Huda N; Chen GY; Kang C; Chia CS; Luo X; Hong W; Poulsen A
Structure; 2015 Nov; 23(11):2076-86. PubMed ID: 26592798
[TBL] [Abstract][Full Text] [Related]
34. Multiple Roles of Vestigial-Like Family Members in Tumor Development.
Yamaguchi N
Front Oncol; 2020; 10():1266. PubMed ID: 32793503
[TBL] [Abstract][Full Text] [Related]
35. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
36. Investigation of activation mechanism and conformational stability of
Sivanandam M; Manjula S; Kumaradhas P
J Biomol Struct Dyn; 2019 Sep; 37(15):4006-4018. PubMed ID: 30301423
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanism study of several inhibitors binding to BRD9 bromodomain based on molecular simulations.
Song LT; Tu J; Liu RR; Zhu M; Meng YJ; Zhai HL
J Biomol Struct Dyn; 2019 Jul; 37(11):2970-2979. PubMed ID: 30058436
[TBL] [Abstract][Full Text] [Related]
38. Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD complexes.
Pobbati AV; Chan SW; Lee I; Song H; Hong W
Structure; 2012 Jul; 20(7):1135-40. PubMed ID: 22632831
[TBL] [Abstract][Full Text] [Related]
39. Novel insights into the dynamics behavior of glucagon-like peptide-1 receptor with its small molecule agonists.
Girdhar K; Dehury B; Kumar Singh M; Daniel VP; Choubey A; Dogra S; Kumar S; Mondal P
J Biomol Struct Dyn; 2019 Sep; 37(15):3976-3986. PubMed ID: 30296922
[TBL] [Abstract][Full Text] [Related]
40. Molecular dynamics simulation and binding free energy studies of novel leads belonging to the benzofuran class inhibitors of Mycobacterium tuberculosis Polyketide Synthase 13.
Cruz JN; Costa JFS; Khayat AS; Kuca K; Barros CAL; Neto AMJC
J Biomol Struct Dyn; 2019 Apr; 37(6):1616-1627. PubMed ID: 29633908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
